Gilead Sciences (GILD) PT Raised to $120 at Oppenheimer on Solid Q2 Beat
Oppenheimer analyst Wendy Lam reiterated an Outperform rating and boosted her price target on Gilead Sciences (NASDAQ: GILD) to $120.00 ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
